Pharmachem Laboratories, Inc. announced it has updated its science dossier that chronicles the evolution of its Phase 2 Carb Controller™ ingredient (known as StarchLite® in Europe), including key research milestones and over 19 separate studies.
“The dossier represents Pharmachem’s ongoing commitment to demonstrating the efficacy and safety of Phase 2 for weight control as well as the control of glucose and the glycemic response to dietary starches” said Mitch Skop, director, new product development. “It is of the utmost importance that we carefully document our ingredient’s scientific pedigree. We feel it is the only way to establish true scientific credibility of our ingredient.”
Over the past decade, Pharmachem has sponsored over a dozen separate human studies of Phase 2 including studies for efficacy, safety and use in functional foods. Several independent studies have also been conducted around the world.
The dossier includes new weight control studies from Mexico and China, plus details of a previously conducted study on Phase 2 in a novel soft chew delivery form. It also includes data sheets, GRAS report and complete product documentation.
Phase 2 was the first clinically studied carb control ingredient and the only one with two structure/function claims:
“May reduce the enzymatic digestion of dietary starches.”
“May aid in weight control when used in conjunction with a sensible diet and exercise.”
The complete dossier is available at www.phase2info.com, under “clinical studies.”
Pharmachem Laboratories, Kearny, NJ, develops, manufactures and supplies a variety of high-quality, efficacious ingredients for the dietary supplement and food industries. Ingredients are manufactured under the strictest quality control in accordance with cGMP standards. For more information, log-on to www.phase2info.com; or call 1-800-526-0609